secwatch.observer — SEC 8-K summary
======================================

Issuer:     Precipio, Inc. (PRPO)
CIK:        0001043961
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001104659-22-027450
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precipio reports preliminary 2021 revenue of $8.9M, up 45% YoY; Q4 revenue $2.4M up 25%
--------------------------------------------------------------------------------

- Preliminary unaudited 2021 revenue $8.9M, up $2.8M (45%) from 2020.
- Q4-2021 revenue $2.4M, a 25% increase from $1.9M in Q4-2020.
- HemeScreen product Q4-2021 revenue $0.4M vs <$0.1M full-year 2020; annualized contracts now >$1.6M.
- 2022 outlook projects meaningful growth in pathology and HemeScreen, aiming to materially reduce cash burn.
- New panels (CLL, BCR-ABL) expected in 2022 to drive revenue per customer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1043961/000110465922027450/0001104659-22-027450-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1043961/000110465922027450/tm227800d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-027450

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer